Skip to main content

Table 1 Characteristics of the 533 GC patients enrolled into this study

From: Long term follow up and retrospective study on 533 gastric cancer cases

Variables Total n (%) Events n (%) Median GC-specific OS (95% CI) (mo) P value
Age (yr)
  ≤ 65 380 (71.3) 178 (46.8) 51.7 (39.7-63.7) < 0.001
  > 65 153 (28.7) 100 (65.4) 28.0 (21.6-34.4)
Gender
  Male 389 (73.0) 192 (49.4) 39.7 (29.9-49.5) 0.019
  Female 144 (27.0) 86 (59.7) 28.0 (17.9-38.1)
Cancer site
  Upper third 156 (29.3) 80 (51.3) 32.6 (25.9-39.3) 0.004
  Middle third 119 (22.3) 61 (51.3) 38.9 (9.4-68.4)
  Lower third 222 (41.7) 112 (50.5) 42.1 (34.2-49.9)
  Whole stomach 36 (6.8) 25 (69.4) 13.2 (10.1-16.3)
Pathological type
  Adeno WD/ID 131 (24.6) 59 (45.0) 42.1 (29.9-54.2) 0.212
  Adeno PD/UN 299 (56.1) 160 (53.5) 34.9 (27.5-42.4)
  Signet ring/mucious Ca 85 (15.9) 49 (57.6) 28.0 (10.9-45.1)
  Others 18 (3.4) 10 (55.6) 33.7 (20.0-47.5)
Surgery type
  Proximal gastrectomy 169 (31.7) 82 (48.5) 35.9 (20.5-51.3) < 0.001
  Distal gastrectomy 268 (50.3) 128 (47.8) 46.6 (38.1-55.1)
  Total gastrectomy 96 (18.0) 68 (70.8) 17.4 (11.3-23.4)
Resection type
  Palliative resection 11 (2.1) 11 (100.0) 9.8 (8.0-11.6) < 0.001
  Curative resection 522 (97.9) 267 (51.1) 38.9 (31.8-46.0)
Other organ resection (n)
  0 507 (95.1) 256(50.5) 39.3 (32.5-46.0) < 0.001
  1 14 (2.6) 11 (78.6) 24.1 (9.6-38.7)
  2 8 (1.5) 7 (87.5) 12.4 (2.7-22.2)
  ≥ 3 4 (0.8) 4 (100.0) 13.6 (2.7-24.4)
HIPEC
  No 505 (94.7) 251 (49.7) 39.7 (32.4-47.0) < 0.001
  Yes 28 (5.3) 27 (96.4) 13.4 (9.6-17.2)
LN status
  N0 172 (32.3) 51 (29.7) 67.3 (59.8-74.8) < 0.001
  N1 112 (21.0) 57 (50.9) 35.9 (26.8-45.0)
  N2 143 (26.8) 86 (60.1) 27.0 (19.9-34.1)
  N3 106 (20.0) 84 (30.5) 14.4 (12.0-16.8)
Tumor invasion
  T1 25 (4.7) 3 (12.0) 75.4 (66.4-84.4) < 0.001
  T2 85 (15.9) 19 (22.4) 72.7 (62.2-83.2)
  T3 2 (0.4) 1 (50.0) 29.1 (10.7-47.4)
  T4a 332 (62.3) 187 (56.3) 33.0 (26.6-39.4)
  T4b 89 (16.7) 68 (76.4) 14.8 (10.8-18.9)
Distant metastases
  No 478 (89.7) 224 (46.9) 42.5 (34.6-50.4) < 0.001
  Yes 55 (10.3) 54 (98.2) 10.6 (9.0-12.1)
TNM staging
  Stage I 79 (14.8) 8 (10.1) 85.2 (76.1-94.3) < 0.001
  Stage II 100 (18.8) 35 (35.0) 53.9 (46.6-61.3)
  Stage IIIA 80 (15.0) 38 (47.5) 40.0 (21.7-58.3)
  Stage IIIB 116 (21.8) 67 (57.8) 28.0 (14.9-41.1)
  Stage IIIC 117 (22.0) 90 (76.9) 14.8 (10.6-19.1)
  Stage IV 41 (7.7) 40 (97.6) 11.1 (9.7-12.4)
Postoperative SAE
  No 458 (85.9) 205 (44.8) 49.8 (32.5-67.0) < 0.001
  Yes 75 (14.1) 73 (97.3) 14.8 (10.0-19.6)
Systemic chemotherapy (cycles)
  0 217 (40.7) 128 (59.0) 26.3 (19.2-33.4) 0.001
  1 to 6 302 (56.7) 142 (47.0) 51.7 (36.6-66.9)
  > 6 14 (2.6) 8 (57.1) 37.8 (16.9-58.7)
IP chemotherapy
  No 521 (97.7) 267 (51.2) 37.0 (29.8-44.2) 0.003
  Yes 12 (2.3) 11 (91.7) 11.1 (7.0-15.1)
  1. GC: gastric cancer; GC-specific OS: gastric cancer-specific overall survival; Adeno WD/ID: well differentiated or intermediately differentiated adenocarcinoma; Adeno PD/UN: poorly differentiated or undifferentiated carinoma; Signet ring/mucious Ca: Signet ring cell carcinoma or mucious adenocarcinoma; HIPEC: hyperthermic intraperitoneal chemotherapy; LN status: lymph node status; SAE: serious adverse event; IP chemotherapy: intraperitoneal chemotherapy.